Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
European Heart Journal

Abstract
The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF).
HF patients with reduced EF (HFrEF) (≤40%,
The primary outcome for both trials was neutral. Empagliflozin was well tolerated in HF patients, with and without T2D, with a safety profile consistent with that previously reported in T2D. Hypothesis-generating improvements in exploratory analyses of secondary endpoints with empagliflozin in HFrEF were observed.
Contributors

JoAnn Lindenfeld
Author

Piotr Ponikowski
Author

Piergiuseppe Agostoni
Author

Javed Butler
Author

Akshay S Desai
Author

Gerasimos Filippatos
Author
National & Kapodistrian University of Athens Medical School Athens , Greece

Jacek Gniot
Author

Michael Fu
Author

Lars Gullestad
Author

Stephen J Nicholls
Author

Josep Redon
Author

Isabelle Schenkenberger
Author

José Silva-Cardoso
Author

Jerzy Krzysztof Wranicz
Author

Martina Brueckmann
Author

Waheed Jamal
Author

Matias Nordaby
Author

Barbara Peil
Author

Ivana Ritter
Author

Anastasia Ustyugova
Author

Cordula Zeller
Author

Afshin Salsali
Author

Stefan D Anker
Author
You may be interested in




